Evolus (NASDAQ:EOLS) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $27.00 target price on the stock.

Several other analysts also recently weighed in on the stock. Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Friday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Stock Performance

Shares of Evolus stock traded down $0.61 during trading hours on Thursday, reaching $13.68. The company’s stock had a trading volume of 1,276,296 shares, compared to its average volume of 588,565. Evolus has a one year low of $7.74 and a one year high of $17.82. The company’s 50 day simple moving average is $16.26 and its 200 day simple moving average is $13.83. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The stock has a market cap of $863.07 million, a P/E ratio of -15.70 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last posted its earnings results on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The firm had revenue of $61.09 million during the quarter, compared to the consensus estimate of $62.81 million. As a group, analysts expect that Evolus will post -0.64 EPS for the current fiscal year.

Insider Transactions at Evolus

In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now owns 82,375 shares in the company, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Evolus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in shares of Evolus by 84.2% in the first quarter. BNP Paribas Financial Markets now owns 405,931 shares of the company’s stock valued at $5,683,000 after purchasing an additional 185,532 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Evolus by 5,627.2% in the second quarter. Assenagon Asset Management S.A. now owns 947,103 shares of the company’s stock valued at $10,276,000 after acquiring an additional 930,566 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Evolus during the 1st quarter worth $11,628,000. Bank of New York Mellon Corp raised its position in shares of Evolus by 24.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock valued at $1,965,000 after acquiring an additional 35,760 shares during the last quarter. Finally, Armistice Capital LLC bought a new position in shares of Evolus in the 2nd quarter worth $3,906,000. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.